Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist- founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previously announced completion of enrollment in Veradermics' first Phase 2/3 trial, this ...